Article Text

Download PDFPDF
Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * See glossary.

  • For correspondence: Dr J A Dormandy, St. George’s Hospital, UK. john.dormandy{at}

  • Sources of funding: Takeda Pharmaceutical Company and Eli Lily and Company.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd